Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
Inhibrx Biosciences, Inc
Nurix Therapeutics, Inc.
AbbVie
DEKA Biosciences
Eli Lilly and Company
Actuate Therapeutics Inc.
GlaxoSmithKline
Stanford University
Fox Chase Cancer Center
City of Hope Medical Center
University of Michigan Rogel Cancer Center
GlaxoSmithKline
National Institutes of Health Clinical Center (CC)